-
Hainan Province Approves Heart-Lung Walking Test Analysis Software as Category II Device
•
The Hainan Medical Products Administration has granted marketing approval to a heart-lung walking test data analysis software following a priority review process. This digital therapy product, classified as a Category II medical device, is designed to assist healthcare professionals in evaluating patients’ exercise cardiopulmonary function, excluding automatic diagnosis. The approval…
-
Hainan Province Unveils Ambitious Three-Year Plan for Digital Health Innovation and Economy Expansion
•
HAIKOU—The People’s Government of Hainan Province has unveiled the “Hainan Province’s Three Year Action Plan for High Quality Development of Digital Health System and Digital Health Economy (2024-2026),” setting its sights on establishing a comprehensive, industry-leading digital health ecosystem. The plan envisions a vibrant innovation landscape that benefits the public,…
-
ArkBio Partners with SDODT to Boost ADHD Treatment Marketing and Commercialization
•
Shanghai Ark Biopharmaceutical Co., Ltd (ArkBio), a Chinese biopharmaceutical company, has entered into a partnership with SDODT, a domestic innovator in digital therapeutics technology. The collaboration aims to enhance the marketing and commercialization efforts for products targeting Attention Deficit Hyperactivity Disorder (ADHD) treatment. ADHD is a prevalent chronic neurodevelopmental disorder…
-
AstraZeneca Launches Evinova to Enhance Global Clinical Development with Digital Health Solutions
•
UK-based AstraZeneca (AZ; NASDAQ: AZN) has launched Evinova, a digital health solutions provider, with the aim of supporting global clinical development. Evinova offers AI-enabled technologies and services to clinical trial (CT) sponsors, clinical research organizations (CROs), CT site care teams, and patients. The new business unit will initially focus on…
